ABUS (Arbutus Biopharma Corp) Earnings per share for the last twelve months

Public company logo of Arbutus (ABUS)

Arbutus Biopharma relies on stable demand within the biotech sector, establishing it as a defensive asset regardless of macroeconomic conditions. The robotization of RNA interference testing accelerates formula discovery, freeing staff from routine tasks. The Hepatitis B cure strategy is based on LNP technologies. The year-over-year EPS dynamics (over 12 months) on this GURU.Markets chart shows that 608.30 reflects the most recent value of the metric.

arbutusbio.com (ABUS): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

ABUS (Arbutus Biopharma): analytical breakdowns and indicator data

- market price and analyst price targets:
- business market valuation indicators:
Fundamental company valuation:Arbutus - ABUS
Mass-produced product of Tekmira Pharmaceuticals

The development of hepatitis B therapy and the outcome of the patent dispute with Moderna determine the financial stability of Arbutus Biopharma (ABUS). An analysis of the EPS YoY TTM shift, reflecting the daily growth rate of earnings per share over the year, allows for an assessment of the real return on capital and the company's ability to service its obligations amid rising interest rates, confirming the business's viability even amidst the risk of compressing market multiples.